Get the Stockscreener App
60.56
2.10%
1.2296
Dexcom Inc stock is traded at $60.56, with a volume of 1.87M.
It is up +2.10% in the last 24 hours and down -5.38% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$59.33
Open:
$60.14
24h Volume:
1.87M
Relative Volume:
0.41
Market Cap:
$23.36B
Revenue:
$4.82B
Net Income/Loss:
$930.40M
P/E Ratio:
25.90
EPS:
2.3381
Net Cash Flow:
$1.43B
1W Performance:
+1.84%
1M Performance:
-5.38%
6M Performance:
+1.62%
1Y Performance:
-28.78%
1-Day Range:
$59.65
$60.83
1-Week Range:
$58.42
$61.55
52-Week Range:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
60.53 | 22.89B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
84.32 | 143.80B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
292.50 | 108.22B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
76.87 | 95.70B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
54.26 | 79.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
79.62 | 44.43B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
Devon Energy stock (US2521311074): Q1 2026 earnings miss revenue, stock drops 9% - AD HOC NEWS
Dexcom gets a new Buy rating at Benchmark on expected margin expansion - Investing.com Canada
Benchmark initiates DexCom stock coverage with buy on G7 launch - Investing.com
Sava Appoints Former Dexcom EMEA Executive as Chief Commercial Officer - Fintech Finance
Benchmark Initiates DexCom at Buy With $77 Price Target - marketscreener.com
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Dexcom stock (US2521311074): Q1 2026 earnings beat estimates with $0.56 EPS - AD HOC NEWS
DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise - MSN
Dexcom Inc. stock (US2521311074): Investor Day in focus as growth outlook draws scrutiny - AD HOC NEWS
symbol__ Stock Quote Price and Forecast - CNN
FinancialContentDexCom, Inc.Common Stock (Nasdaq:DXCM) Stock Quote - FinancialContent
How Investors May Respond To DexCom (DXCM) Strong Q1 2026 Earnings And Reaffirmed Revenue Outlook - Sahm
BTIG Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Dexcom Inc. stock (US2521311074): Q1 earnings beat lifts shares near $61 on Nasdaq - AD HOC NEWS
Alphabet reports stake in PayPay and CME Group, dissolves in Dexcom - marketscreener.com
DXCM Stock Price, Quote & Chart | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DexCom's (NASDAQ:DXCM) Strong Earnings Are Of Good Quality - Yahoo Finance
5 Insightful Analyst Questions From DexCom’s Q1 Earnings Call - Barchart.com
DexCom (DXCM) Reports Q1 2026 Revenue of $1.19B with 15% Growth - Insider Monkey
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom - TMX Newsfile
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom (DXCM) Q1 2026 Earnings Transcript - AOL.com
DexCom : Trade Association Report 2025 - marketscreener.com
Argus Adjusts Price Target on DexCom to $86 From $90 - marketscreener.com
Dexcom to Host Investor Day on May 14, 2026 - BioSpace
Alert from law firm tagged to Dexcom withdrawn - marketscreener.com
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
3 reasons analysts love DexCom - MSN
9 Stocks That Could Defy the ’Sell in May and Go Away’ Trend This Time - Investing.com
3 Reasons Analysts Love DexCom - MarketBeat
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
JPMorgan prices $345K DexCom‑linked callable notes | JPM Prospectus Summary - Stock Titan
PFA Pension Forsikringsaktieselskab Acquires New Stake in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. (DXCM) Stock Analysis: Unveiling a 36% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Should DexCom’s Margin Gains and Expanded Coverage Require Action From DexCom (DXCM) Investors? - Yahoo Finance
Canaccord Genuity Adjusts Price Target on DexCom to $100 From $95, Maintains Buy Rating - Moomoo
Dexcom, Inc. Q1 2026 Financial Results: Strong Revenue, Earnings, and Forward-Looking Statements - Minichart
Research Alert: CFRA Maintains Hold Rating On Shares Of Dexcom, Inc. - Moomoo
DexCom Faces Potential Headwinds in 2026, but Expanding Reimbursement Offers Long-Term Prospects - Morningstar
DexCom Medicare Coverage NCD Remains Biggest 2026 Catalyst, RBC Says - marketscreener.com
JPMorgan Adjusts DexCom Price Target to $65 From $75 - marketscreener.com
DexCom, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:DXCM) 2026-05-01 - Seeking Alpha
DexCom, Inc. (NASDAQ:DXCM) Q1 2026 Earnings Call Transcript - Insider Monkey
DexCom, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Dexcom reports 15% YoY revenue uptick in Q1 yet maintains prior FY26 outlook - Yahoo Finance
DexCom Inc (NASDAQ:DXCM): A GARP Stock with Affordable Growth and Strong Fundamentals - ChartMill
Barclays Adjusts Price Target on DexCom to $67 From $72, Maintains Underweight Rating - marketscreener.com
Leerink Partners Adjusts Price Target on DexCom to $80 From $95, Maintains Outperform Rating - marketscreener.com
Bernstein Adjusts Price Target on DexCom to $77 From $83, Maintains Outperform Rating - marketscreener.com
Bernstein SocGen lowers DexCom stock price target on valuation By Investing.com - Investing.com Canada
Raymond James Adjusts Price Target on DexCom to $81 From $83, Maintains Strong Buy Rating - marketscreener.com
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):